Baptist Health Study Suggests Plant-Based Amino Acid Drink Lessens Chemotherapy Side Effects
Baptist Health Louisville (Kentucky) is looking for ways to help cancer patients fight the side effects of chemotherapy.
Researchers are studying a new plant-based amino acid drink, Enterade, product of UF startup and UF Innovate | Accelerate alumnus company Entrinsic Bioscience, LLC.
Entrinsic Bioscience Shares Breakthrough in Rehydration Technology
Groundbreaking research conducted by a team of leading researchers at Entrinsic Bioscience (EBS) and the University of Florida revealed significant findings that will change the way we understand amino acid combinations and represents the next generation of Oral Rehydration Solutions (ORS).
Entrinsic Bioscience Steps Closer to Amino Acid Formulation as Therapy for Cystic Fibrosis
Entrinsic Bioscience and its licensee Nuvara Therapeutics announce they are one step closer to using RxAA formulations as a therapy for patients with Cystic Fibrosis Class I mutations
Entrinsic Bioscience Announces Tool with Potential for Development of New Therapies Addressing Constipation
Entrinsic Bioscience announces a tool to measure intestinal peristalsis that could lead to the development of therapeutic agents for constipation, including Irritable Bowel Syndrome-Constipation (IBS-C).
Entrinsic Bioscience Demonstrates Breakthrough GI Barrier Benefits
Entrinsic Bioscience, a pioneering life sciences company incubating at UF Innovate | Accelerate at Sid Martin Biotech, announced results from a new clinical study at renowned Monash University, in Melbourne, Australia. Entrinsic has successfully demonstrated the efficacy of two UF patent-protected formulas, utilizing precise combinations of amino acids, which enabled them to provide targeted gastrointestinal (GI) health and wellness benefits.
entrinsic bioscience Secures $49 Million in Financing To Accelerate Development and Commercialization of Next Generation Functional Ingredients and Active Pharmaceutical Ingredients
UF startup and UF Innovate | Sid Martin Biotech resident entrinsic bioscience (EBS), a company pioneering a next-generation protein modulation technology, announced that it has secured $49 million in non-dilutive growth capital from Jefferies Group LLC’s subsidiary, Jefferies Funding LLC (Jefferies).
UF Researcher Finds a Way to Mitigate Acute Respiratory Distress Syndrome (ARDS), a Complication of Coronavirus Infection
Why would a doctor specializing in gastrointestinal disorders be interested in therapy for COVID-19, a primarily pulmonary disease? The answer lies in a seemingly convoluted link between the gastrointestinal tract and the lungs: water.
entrinsic bioscience Secures U.S. Patent Grant for Breakthrough Respiratory Disease Program
UF startup and UF Innovate | Sid Martin Biotech resident client entrinsic bioscience (EBS), a company pioneering a next-generation protein modulation technology, announced that it has been granted U.S. Patent No. (USPN) 10,758,507 (‘507 patent) for novel therapeutic formulations in the treatment of a range of respiratory diseases with significant unmet medical needs. EBS is […]
Dr. Sadasivan Vidyasagar, Associate Professor at University of Florida, and entrinsic bioscience CEO Stephen Gatto, Receive University of Florida’s ‘Invention of the Year 2020’ Award
UF Innovate | Sid Martin Biotech resident client entrinsic bioscience (EBS), a company pioneering a next-generation protein modulation technology, announced that its co-founder, Dr. Sadasivan (Sagar) Vidyasagar, an associate professor at the University of Florida, and entrinsic bioscience’s CEO, Stephen Gatto, received the “Invention of the Year 2020” Award from UF Innovate | Tech Licensing for their novel amino-acid […]
entrinsic bioscience Strengthens Leadership Team with Appointment of Mario Wanderley as Chief Financial Officer and Accelerates Product Development with New Research Facility
UF startup and UF Innovate | Sid Martin Biotech resident client entrinsic bioscience (EBS), a company pioneering a next-generation protein modulation technology, announced the appointment of Mario Wanderleyas Chief Financial Officer. Mr. Wanderley brings 23 years of financial, operational, and strategic expertise to EBS, with significant experience in the medical device, technology, software, telecommunications, and […]